Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit

King, James P.; Palmer, Daniel H.; Johnson, Philip J.; Ross, Paul; Hubner, Richard A; Sumpter, Katherine; Darby, Suzanne; Braconi, Chiara; Iwuji, Chinenye; Swinson, Daniel; Collins, Peter L.; Patel, Kinnari; Nobes, Jenny; Muazzam, Iqtedar A; Blesing, Claire; Kirkwood, Amy A.; Nash, S; Meyer, Tim

doi:10.1016/j.clon.2016.11.012

Cited by 31 publications

(31 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the evaluation according to the CP-A or CP-B scores, there was no difference in this frequency. The adverse reactions reported with high frequency in this study agree with data reported in the literature [7,11,18,21,22]. Diarrhea was described as an adverse reaction relative to a better response to treatment with SOR [10,21].…”

Section: Discussionsupporting

confidence: 82%

“…Hypertension as well is associated with a better response to the therapy, but it was not a frequent finding in the present study [23]. Previous studies have reported similarities between the rates of adverse reactions in patients with CP-A and CP-B scores, demonstrating that SOR can be administered to both groups with safety and tolerability [5,10,18,19,22]. Abou-Alfa et al [24] reported differences in the incidence of adverse reactions among patients with CP-A and CP-B; however, it cannot be determined if such differences are related to the drug or the progression of the disease.…”

Section: Discussionmentioning

confidence: 47%

See 1 more Smart Citation

Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience

Longo

Freitas

Santos

et al. 2018

Dig Dis

View full text Add to dashboard Cite

Introduction: Sorafenib (SOR) has proved to be effective in patients with advanced hepatocellular carcinoma (HCC), since overall survival was higher in phase III clinical trials; however, disease progression can occur. Objectives: The study aimed to describe real-life experience in advanced HCC treatment with SOR at a university hospital in Brazil and to estimate the number of patients with indication of second-line therapy. Methods: This is a retrospective study that included cases of HCC with prescription of SOR based on real-life practice between 2011 and 2016. Demographic, clinical, and laboratory data were collected. Results: From 572 patients with HCC, SOR was prescribed in 103 cases. From them, 62.1% were classified as Child-Pugh (CP)-A, 54.4% as Barcelona Clinic Liver Cancer (BCLC)-C, and 74 (71.8%) started treatment. Overall survival was 25.5 (95% CI 17.0–34.1) months and 1-year survival was greater in patients who received SOR than in non-treated (88.7 vs. 44.4%, p < 0.001). There was no difference in survival between BCLC-B and C (p = 0.405), as well as CP-A and B (p = 0.919). In 21.6% of the patients, a second-line therapy with regorafenib was indicated. Conclusion: In this real-life study, SOR significantly increased the survival rate by 1 year in patients with advanced HCC regardless of BCLC staging and CP score. Second-line therapy would be indicated in 21.6% of cases.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 47%

Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience

Longo

Freitas

Santos

et al. 2018

Dig Dis

View full text Add to dashboard Cite

show abstract

“…18 A recent multicenter study from the United Kingdom also demonstrated Child-Pugh class, performance status, and albumin-bilirubin grade as prognostic factors in sorafenib-treated patients. 19 Other multicenter observational studies have recently demonstrated similar results of Child-Pugh class as the main determining factor of overall survival. [20][21][22] PVT was another frequently reported prognostic factor.…”

Section: Discussionmentioning

confidence: 65%

“…In the exploratory analysis of the two phase 3 studies, the presence of macrovascular invasion, high AFP, and neutrophil‐to‐lymphocyte ratio demonstrated a poor prognosis of overall survival . A recent multicenter study from the United Kingdom also demonstrated Child‐Pugh class, performance status, and albumin‐bilirubin grade as prognostic factors in sorafenib‐treated patients . Other multicenter observational studies have recently demonstrated similar results of Child‐Pugh class as the main determining factor of overall survival .…”

Section: Discussionmentioning

confidence: 85%

The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment

Yeh

Huang

et al. 2019

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Sorafenib is currently the first‐line therapy for advanced hepatocellular carcinoma (aHCC) patients. However, the outcomes and prognostic factors of sorafenib therapy have not been well investigated. We aimed to investigate the pretreatment factors and outcomes among Taiwanese aHCC patients receiving sorafenib treatment. A total of 347 patients with aHCC and well‐compensated liver cirrhosis (Child‐Pugh A) status receiving sorafenib were consecutively enrolled from March 2013 through December 2016. Pre‐treatment clinical data and viral hepatitis markers were collected and analyzed with their outcomes. The primary endpoint of the study was overall survival. The factors associated with overall survival were also investigated. The median overall survival of all the patients was 238 days (range, 9‐1504 days) with a 1‐year overall survival of 43.2%. Positive hepatitis B surface antigen and absence of portal vein thrombosis (PVT) were independent factors associated with better overall survival. The median duration of sorafenib therapy was 93.0 days (range, 4‐1504 days). After stopping sorafenib, the median survival was 93.0 days (range, 1‐1254 days). The 1‐year survival after stopping sorafenib was 21.2%. In chronic hepatitis B patients, total bilirubin level was the only factor associated with overall survival. Hepatitis C antibody RNA negativity, tumor size, PVT, and white blood cell count were the independent factors associated with survival among those chronic hepatitis C patients. There were different prognostic factors stratified by viral etiologies in aHCC patients receiving sorafenib. Viral eradication increased survival in chronic hepatitis C patients.

show abstract

“…[ ][ ] There are many studies in the literature that reveal antimicrobial, anticonvulsant, anti‐inflammatory, antiplasmodial, antidepressant, antiviral, antituberculosis, and cytotoxic activities of the diarylurea containing compounds. Also sorafenib IV and linifanib V, [ ][ ] which are used in the treatment of cancer, are good examples of bioactive compounds containing the diarylurea unit ( Fig. ).…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Biological Evaluation of Novel 1‐(4‐(Hydroxy(1‐oxo‐1,3‐dihydro‐2H‐inden‐2‐ylidene)methyl)phenyl)‐3‐phenylurea Derivatives

Gezegen

Hepokur

Tutar

et al. 2017

Chemistry & Biodiversity

View full text Add to dashboard Cite

A series of novel phenylurea containing 2-benzoylindan-1-one derivatives 3a - 3j were synthesized from the reaction of phenylurea-substituted acetophenones 1a - 1j with phthalaldehyde 2 under mild reaction conditions in good yields. All synthesized compounds were characterized by spectroscopic methods. The obtained compounds (3a - 3j) were evaluated for anticancer activity against HeLa and C6 cell lines. Antiproliferative activity was determined by the BrdU proliferation ELISA assay, 3f and 3g were found to be most active compounds. The compounds were also screened for antimicrobial activity and all compounds showed remarkable activity against used microorganisms.

show abstract

Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit

Abstract: Background: Sorafenib is the current standard treatment for advanced hepatocellular

Cited by 31 publications

References 23 publications

Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience

Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience

The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment

Synthesis and Biological Evaluation of Novel 1‐(4‐(Hydroxy(1‐oxo‐1,3‐dihydro‐2H‐inden‐2‐ylidene)methyl)phenyl)‐3‐phenylurea Derivatives

Contact Info

Product

Resources

About